Twelve‐Month Clinical and Cost Outcomes of Removal of Cytomegalovirus Intravenous Immune Globulin From Heart Transplantation Protocol
Removing CMV-IVIG from a heart transplant protocol was associated with cost avoidance without worsened outcomes in CMV DNAemia. CMV-IVIG likely does not have significant benefits for preventing CMV DNAemia with concomitant universal antiviral prophylaxis in heart transplant recipients.
Authors
- Robert L. Page (ORCID: https://orcid.org/0000-0002-9288-694X)
- Emily Sartain (ORCID: https://orcid.org/0000-0002-4667-8074)
- M. Mohan Rao (ORCID: https://orcid.org/0000-0002-8829-8002)
Institutions
- University of Colorado Hospital (US)
- NYU Langone Health (US)
- University of Montana (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/ctr.70147
- Citations
- 2
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 2.71